Search

Your search keyword '"Steeghs N"' showing total 671 results

Search Constraints

Start Over You searched for: Author "Steeghs N" Remove constraint Author: "Steeghs N"
671 results on '"Steeghs N"'

Search Results

5. Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes

13. Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients

14. Referral patterns of GIST patients: data from a nationwide study

23. Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns (Nature Communications, (2020), 11, 1, (728), 10.1038/s41467-019-13825-8)

27. Local recurrence in primary localised resected gastrointestinal stromal tumours: A registry observational national cohort study including 912 patients.

28. Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data.

29. A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors.

30. Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC).

31. Local treatment in metastatic GIST patients: A multicentre analysis from the Dutch GIST Registry.

32. The association of having a monitoring or blunting coping style with psychological distress, health-related quality of life and satisfaction with healthcare in gastrointestinal stromal tumour (GIST) patients.

33. The use of microtracers in food-effect trials : An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib

34. The use of microtracers in food-effect trials: An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib

35. Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients

36. Optimizing carboplatin dosing by an improved prediction of carboplatin clearance using a CT-enhanced estimate of renal function

38. Actualisation des données de phase I de recherche de dose et premières données de la phase d’expansion du tarlatamab, un anticorps bispécifique ciblant la protéine DLL3 et engageant les lymphocytes T, dans le cancer bronchique à petites cellules (CBPC)

39. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

40. 147P Characterizing CRS in phase I study of DLL3-targeted T cell engager tarlatamab in small cell lung cancer

42. Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

43. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study

44. OA12.05 Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer

49. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

Catalog

Books, media, physical & digital resources